Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/16437
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVIDAL VERA, Pia-
dc.contributor.authorLEMMENS, Evi-
dc.contributor.authorAVILA MACAYA, Ariel-
dc.contributor.authorVANGANSEWINKEL, Tim-
dc.contributor.authorChalaris, A.-
dc.contributor.authorRose-John, S.-
dc.contributor.authorHENDRIX, Sven-
dc.date.accessioned2014-03-18T11:59:09Z-
dc.date.available2014-03-18T11:59:09Z-
dc.date.issued2013-
dc.identifier.citationCELL DEATH & DISEASE, 4(12), (ART N° e954)-
dc.identifier.issn2041-4889-
dc.identifier.urihttp://hdl.handle.net/1942/16437-
dc.description.abstractA disintegrin and metalloprotease 17 (ADAM17) is a sheddase with important substrates including tumor necrosis factor-alpha (TNF-alpha) and its receptors, the p75 neurotrophin receptor (p75NTR), and members of the epidermal growth factor family. The rationale of this study was to inhibit ADAM17-induced shedding of soluble TNF-alpha in order to reduce detrimental inflammation after spinal cord injury (SCI). However, using the specific ADAM17 blocker BMS-561392 in neuronal and glial cell cultures, we show that proper functioning of ADAM17 is vital for oligodendrocyte and microglia survival in a p44 MAPK-dependent manner. In contrast, genetic ablation of ADAM17 specifically increases microglial death. Surprisingly, although blocking ADAM17 in vivo does not substantially change the ratio between membrane-bound and soluble TNF-alpha, it increases expression of the pro-apoptotic marker Bax and microglial apoptosis while impairing functional recovery after SCI. These data suggest that ADAM 17 is a key survival factor for microglial cells after SCI.-
dc.description.sponsorshipWe thank Dr. F Kirchhoff and Dr. Anja Scheller (University of Saarland, Germany) to provide us with the PLP-eCFP mice. We thank Bristol-Myers Squibb for providing the specific ADAM 17 inhibitor BMS-561392 to perform the study. This study was supported in part by grants from Deutsche Forschungsgemeinschaft (SPP1394), SFB877 project A1 to AC and SRJ, and from Research Foundation Flanders - FWO (G.0834.11N, G.0389.12N, GOA1413N) to SH and EL (1.2.703.10N), and to PV by the transnational University Limburg (tUL).-
dc.language.isoen-
dc.rights© 2013 Macmillan Publishers Limited All rights reserved.-
dc.subject.otherTACE; TNF-alpha; ERK; MAPK; apoptosis; macrophage/microglia-
dc.titleADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice-
dc.typeJournal Contribution-
dc.identifier.issue12-
dc.identifier.volume4-
local.format.pages13-
local.bibliographicCitation.jcatA1-
dc.description.notesHendrix, S (reprint author), Hasselt Univ, Dept Morphol, Martelarenlaan 42, B-3500 Hasselt, Belgium. sven.hendrix@uhasselt.be-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnre954-
dc.identifier.doi10.1038/cddis.2013.466-
dc.identifier.isi000329161300015-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
item.contributorVIDAL VERA, Pia-
item.contributorChalaris, A.-
item.contributorRose-John, S.-
item.contributorVANGANSEWINKEL, Tim-
item.contributorAVILA MACAYA, Ariel-
item.contributorHENDRIX, Sven-
item.contributorLEMMENS, Evi-
item.fullcitationVIDAL VERA, Pia; LEMMENS, Evi; AVILA MACAYA, Ariel; VANGANSEWINKEL, Tim; Chalaris, A.; Rose-John, S. & HENDRIX, Sven (2013) ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice. In: CELL DEATH & DISEASE, 4(12), (ART N° e954).-
item.validationecoom 2015-
crisitem.journal.issn2041-4889-
crisitem.journal.eissn2041-4889-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
vidal 1.pdfpublished version3.44 MBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

12
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

18
checked on Jul 1, 2022

Page view(s)

76
checked on Jul 3, 2022

Download(s)

96
checked on Jul 3, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.